HER2-negative

About

Biomarker Type: Protein expression

Present: True

Marker: Human epidermal growth factor receptor 2 (HER2)

Unit: status

Equality: =

Value: Negative


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib HC
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 somatic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab FDA
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab FDA
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab FDA
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib FDA
Sensitivity (+) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab HC
Sensitivity (+) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib HC
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab FDA
Sensitivity (+) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib HC
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib FDA
Sensitivity (+) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab HC
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Elacestrant FDA
Sensitivity (+) ER positive, ESR1 oncogenic variants, HER2-negative Invasive Breast Carcinoma Imlunestrant FDA
Sensitivity (+) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan FDA
Sensitivity (+) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab FDA
Sensitivity (+) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib FDA
Sensitivity (+) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel HC
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA
Sensitivity (+) ER positive, HER2-negative, PIK3CA somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant FDA